Grufity logo
Grufity logo
CVM

CVM - CEL-SCI Corp Stock Price, Fair Value and News

$1.010.00 (0.00%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

Price Targets

CVM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CVM Price Action

Last 7 days

-27.5%

Last 30 days

-30.1%

Last 90 days

-72.2%

Trailing 12 Months

-55.6%

CVM RSI Chart

CVM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CVM Valuation

Market Cap

8.6M

Price/Earnings (Trailing)

-0.38

Price/Sales (Trailing)

28.26

EV/EBITDA

-0.35

Price/Free Cashflow

-0.51

CVM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

CVM Fundamentals

CVM Revenue

Revenue (TTM)

462.8K

CVM Earnings

Earnings (TTM)

-22.7M

Earnings Growth (Yr)

16.84%

Earnings Growth (Qtr)

0.07%

CVM Profitability

EBT Margin

-7536.20%

Return on Equity

-330.21%

Return on Assets

-128.2%

Free Cashflow Yield

-194.22%

CVM Investor Care

Shares Dilution (1Y)

202.06%

Diluted EPS (TTM)

-2.31

CVM Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2019469.7K466.2K462.8K-
2018--476.6K473.1K
2017207.5K342.0K--
201698.0K85.5K73.0K-
2015116.9K112.5K110.5K-
2014120.0K121.4K122.9K120.2K
2013116.6K116.8K117.1K118.5K
2012--116.1K116.3K
2011--956.2K-
2010----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About CEL-SCI Corp

CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
0
 WEBSITEhttps://cel-sci.com
 SECTORHealthcare
 INDUSTRYBiotechnology

CEL-SCI Corp Frequently Asked Questions

CVM is the stock ticker symbol of CEL-SCI Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of CEL-SCI Corp is 8.58 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, CVM's PE ratio (Price to Earnings) is -0.38 and Price to Sales (PS) ratio is 28.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CVM PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, CEL-SCI Corp has provided -0.442 (multiply by 100 for percentage) rate of return.